Abstract
Anticoagulants are used to prevent the formation and extension of blood clots in various disorders as prophylactic agents for thrombo-embolic disorders. Designing of specific inhibitors against molecular targets that play a pivotal role in the coagulation cascade is indispensable. Clotting Factor Xa is one such attractive target for the design of new oral anticoagulants because of the unique role factor Xa plays in the coagulation cascade as a connection between the extrinsic and intrinsic pathways. Application of computational techniques in drug discovery process helps in identifying parameters which can lead to achieve better pharmacological profile. The docking interactions and QSAR studies performed on series of 4-methy-3-(6-[phenyl methylene] amino} pyridine-3-yl)-2H chromen-2-one derivatives provide significant insights for designing of better ligands as anticoagulants.
Keywords: 3D QSAR, Activated Partial Thromboplastin Time, Chromen-2-one, Molecular Docking, Prothrombin time, Anticoagulants, Pharmaceutical Chemistry, Clotting Factor, pyridine, thromboplastin
Medicinal Chemistry
Title:Identification of Structural Features for 4-Methyl-3-(6-[Phenyl Methylene] Amino} Pyridine-3-yl)-2h Chromen-2-One Derivatives as Clotting Factor XA Inhibitors
Volume: 8 Issue: 2
Author(s): Kundan B. Ingale, Manish S. Bhatia
Affiliation:
Keywords: 3D QSAR, Activated Partial Thromboplastin Time, Chromen-2-one, Molecular Docking, Prothrombin time, Anticoagulants, Pharmaceutical Chemistry, Clotting Factor, pyridine, thromboplastin
Abstract: Anticoagulants are used to prevent the formation and extension of blood clots in various disorders as prophylactic agents for thrombo-embolic disorders. Designing of specific inhibitors against molecular targets that play a pivotal role in the coagulation cascade is indispensable. Clotting Factor Xa is one such attractive target for the design of new oral anticoagulants because of the unique role factor Xa plays in the coagulation cascade as a connection between the extrinsic and intrinsic pathways. Application of computational techniques in drug discovery process helps in identifying parameters which can lead to achieve better pharmacological profile. The docking interactions and QSAR studies performed on series of 4-methy-3-(6-[phenyl methylene] amino} pyridine-3-yl)-2H chromen-2-one derivatives provide significant insights for designing of better ligands as anticoagulants.
Export Options
About this article
Cite this article as:
Kundan B. Ingale, Manish S. Bhatia , Identification of Structural Features for 4-Methyl-3-(6-[Phenyl Methylene] Amino} Pyridine-3-yl)-2h Chromen-2-One Derivatives as Clotting Factor XA Inhibitors , Medicinal Chemistry 2012; 8 (2) . https://dx.doi.org/10.2174/157340612800493728
DOI https://dx.doi.org/10.2174/157340612800493728 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Dermatologic Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design Pharmacological Strategies for Inhibition of Thrombin Activity
Current Pharmaceutical Design Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
Recent Patents on Anti-Cancer Drug Discovery Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the “Low-Risk” Patients?
Current Drug Targets Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis
Current Medicinal Chemistry Overview of Current Practice and Future Trends in Thromboprophylaxis for General Surgery
Vascular Disease Prevention (Discontinued) Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
Current Drug Metabolism Novel Oral Anticoagulants in Peripheral Arterial and Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanical Thrombectomy in Acute Ischaemic Stroke: A Review of the Literature, Clinical Effectiveness and Future Use
CNS & Neurological Disorders - Drug Targets Novel Therapeutic Agents in the Management of Hemorrhage and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design Combination of Multifunctional Nanoparticles and Interventional Techniques Makes Each Other Going Further in the Field of Cancer Treatment
Current Drug Metabolism Fc-Independent Phagocytosis: Implications for Intravenous IgG Therapy in Immune Thrombocytopenia
Cardiovascular & Hematological Disorders-Drug Targets Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe?
Current Pharmaceutical Design